GMAB – Genmab A/S
GMAB — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
1.28
Margin Of Safety %
1
Put/Call OI Ratio
0.17
EPS Next Q Diff
0.2
EPS Last/This Y
-0.23
EPS This/Next Y
0.56
Price
31.25
Target Price
37.72
Analyst Recom
1.31
Performance Q
Upside
N/A
Beta
0.82
Ticker: GMAB
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-07-13 | GMAB | 28.81 | 0.13 | 0.05 | 66891 |
| 2026-07-14 | GMAB | 28.73 | 0.13 | 0.28 | 66945 |
| 2026-07-15 | GMAB | 29.08 | 0.13 | 5.50 | 66923 |
| 2026-07-16 | GMAB | 29 | 0.13 | 2.22 | 66930 |
| 2026-07-17 | GMAB | 28.71 | 0.13 | 1.13 | 66943 |
| 2026-07-20 | GMAB | 27.9 | 0.12 | 0.13 | 62949 |
| 2026-07-21 | GMAB | 28.36 | 0.12 | 0.29 | 62793 |
| 2026-07-22 | GMAB | 28.84 | 0.13 | 1.15 | 62967 |
| 2026-07-23 | GMAB | 29.17 | 0.13 | 0.19 | 63008 |
| 2026-07-24 | GMAB | 28.88 | 0.13 | 0.18 | 63193 |
| 2026-07-27 | GMAB | 28.8 | 0.13 | 4.25 | 63379 |
| 2026-07-28 | GMAB | 28.99 | 0.13 | 999.99 | 63414 |
| 2026-07-29 | GMAB | 28.54 | 0.13 | 0.20 | 63358 |
| 2026-07-30 | GMAB | 28.63 | 0.13 | 4.42 | 63357 |
| 2026-07-31 | GMAB | 28.86 | 0.13 | 0.58 | 63829 |
| 2026-08-03 | GMAB | 28.68 | 0.13 | 0.76 | 63828 |
| 2026-08-04 | GMAB | 29.01 | 0.13 | 0.01 | 63857 |
| 2026-08-05 | GMAB | 29.27 | 0.13 | 2.05 | 63901 |
| 2026-08-07 | GMAB | 31.23 | 0.17 | 0.06 | 66162 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-07-13 | GMAB | 28.80 | - | 7.0 | 1.05 |
| 2026-07-14 | GMAB | 28.73 | - | -13.0 | 1.05 |
| 2026-07-15 | GMAB | 29.07 | - | 22.7 | 1.05 |
| 2026-07-16 | GMAB | 29.00 | - | -2.5 | 1.05 |
| 2026-07-17 | GMAB | 28.70 | - | -8.9 | 1.08 |
| 2026-07-20 | GMAB | 27.91 | - | -16.9 | 1.08 |
| 2026-07-21 | GMAB | 28.36 | - | 11.2 | 1.08 |
| 2026-07-22 | GMAB | 28.85 | - | 26.9 | 1.08 |
| 2026-07-23 | GMAB | 29.17 | - | 12.3 | 1.08 |
| 2026-07-24 | GMAB | 28.87 | - | 5.9 | 1.32 |
| 2026-07-27 | GMAB | 28.80 | - | 16.3 | 1.32 |
| 2026-07-28 | GMAB | 28.98 | - | 0.1 | 1.32 |
| 2026-07-29 | GMAB | 28.52 | - | 3.1 | 1.32 |
| 2026-07-30 | GMAB | 28.63 | - | 29.1 | 1.32 |
| 2026-07-31 | GMAB | 28.86 | - | 51.7 | 1.32 |
| 2026-08-03 | GMAB | 28.68 | - | 15.8 | 1.32 |
| 2026-08-04 | GMAB | 28.68 | - | 15.8 | 1.32 |
| 2026-08-05 | GMAB | 29.27 | - | 30.9 | 1.32 |
| 2026-08-06 | GMAB | 29.86 | - | 42.2 | 1.32 |
| 2026-08-07 | GMAB | 31.25 | - | 82.2 | 1.32 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-07-13 | GMAB | 0.00 | -0.21 | 1.41 |
| 2026-07-14 | GMAB | 0.00 | -0.21 | 1.41 |
| 2026-07-15 | GMAB | 0.00 | -0.21 | 1.41 |
| 2026-07-16 | GMAB | 0.00 | -0.21 | 1.41 |
| 2026-07-17 | GMAB | 0.00 | -0.21 | 1.41 |
| 2026-07-20 | GMAB | 0.00 | -0.21 | 1.41 |
| 2026-07-21 | GMAB | 0.00 | -0.21 | 1.41 |
| 2026-07-22 | GMAB | 0.00 | -0.21 | 1.41 |
| 2026-07-23 | GMAB | 0.00 | -0.21 | 1.41 |
| 2026-07-24 | GMAB | 0.00 | -0.21 | 1.41 |
| 2026-07-27 | GMAB | 0.00 | -0.08 | 1.28 |
| 2026-07-28 | GMAB | 0.00 | -0.08 | 1.28 |
| 2026-07-29 | GMAB | 0.00 | -0.08 | 1.28 |
| 2026-07-30 | GMAB | 0.00 | -0.08 | 1.28 |
| 2026-07-31 | GMAB | 0.00 | -0.08 | 1.28 |
| 2026-08-03 | GMAB | 0.00 | -0.09 | 1.28 |
| 2026-08-04 | GMAB | 0.00 | -0.09 | 1.28 |
| 2026-08-05 | GMAB | 0.00 | -0.09 | 1.28 |
| 2026-08-06 | GMAB | 0.00 | -0.09 | 1.28 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
0.15
Avg. EPS Est. Current Quarter
0.35
Avg. EPS Est. Next Quarter
0.35
Insider Transactions
Institutional Transactions
-0.09
Beta
0.82
Average Sales Estimate Current Quarter
1076
Average Sales Estimate Next Quarter
7627
Fair Value
31.71
Quality Score
88
Growth Score
96
Sentiment Score
79
Actual DrawDown %
36.3
Max Drawdown 5-Year %
-63.1
Target Price
37.72
P/E
22.49
Forward P/E
17.81
PEG
1.01
P/S
4.54
P/B
3.22
P/Free Cash Flow
20.27
EPS
1.33
Average EPS Est. Cur. Y
1.32
EPS Next Y. (Est.)
1.88
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
21.06
Relative Volume
2.62
Return on Equity vs Sector %
-12.9
Return on Equity vs Industry %
3.2
EPS 1 7Days Diff
1.3
EPS 1 30Days Diff
1.32
EBIT Estimation
82.2
No data found for GMAB
GMAB — P/E HistoricalBiotechnology
Genmab A/SSector: Healthcare
Industry: Biotechnology
Employees: 3119
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R/R DLBCL and FL, first line DLBCL and FL, B-cell non-Hodgkin lymphoma, R/R chronic lymphocytic leukemia and Richter's syndrome, and aggressive mature B-cell neoplasms in pediatric patients; tisotumab vedotin for solid tumors; Acasunlimab for solid tumors and non-small cell lung cancer (NSCLC); Rinatabart Sesutecan for platinum resistant ovarian cancer and solid tumors; GEN1059, GEN1055, and GEN1057 for solid tumors; and GEN1286 for advanced solid tumors. In addition, the company offers DARZALEX/DARZALEX FASPRO for multiple myeloma (MM) and light-chain Amyloidosis; RYBREVANT for NSCLC; TECVAYLI and TALVEY for R/R MM; Kesimpta for Relapsing multiple sclerosis; and TEPEZZA for thyroid eye disease. Further, it is developing Amivantamab for recurrent/metastatic head and neck cancer, and advanced or metastatic colorectal cancer; Amlenetug for multiple system atrophy; Inclacumab for vaso-occulsive crises in sickle cell diseases; and Mim8 for hemophilia A. The company has a collaboration agreement with AbbVie Inc., Pfizer Inc., BioNTech SE, Johnson & Johnson, Medarex, Inc., Bristol Myers Squibb Corporation, Lundbeck A/S, Amgen Inc., Novo Nordisk A/S, and argenx. Genmab A/S was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
GMAB
Latest News
—
Caricamento notizie per GMAB…
stock quote shares GMAB – Genmab A/S Stock Price stock today
news today GMAB – Genmab A/S stock forecast ,stock prediction 2023 2024 2025
marketwatch GMAB – Genmab A/S yahoo finance google finance
stock history GMAB – Genmab A/S invest stock market
stock prices GMAB premarket after hours
ticker GMAB fair value insiders trading